Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rangering i aksjer #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aksjekurs
$64.97
Sist synkronisert: 2024-05-20
Markedsverdi
$1.97B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategori

P/S-forhold for Alpine Immune Sciences, Inc. (ALPN)
P/S-forhold per August 2026 TTM: 75.70
Ifølge Alpine Immune Sciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 75.70. Ved slutten av 2022 hadde selskapet et P/S-forhold på 8.17.
P/S-historikk for Alpine Immune Sciences, Inc. fra 2012 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 75.70 367.56%
2023 16.19 98.02%
2022 8.17 -45.69%
2021 15.05 -46.46%
2020 28.11 -30.62%
2019 40.52 -43.96%
2018 72.29 72.38%
2017 41.94 256.51%
2016 11.76 -92.02%
2015 147.42 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -86.57%
US
10.13 -86.62%
NL
2.95 -96.10%
AU
11.28 -85.10%
US
- -
CH